Financing › Details

Lytix Biopharma–SEVERAL: investment, 201512 capital increase NOK80m w 224.2k new shares at NOK350/share to existent + new shareholders

 

Period Period 2015-12-15
  Predecessor Lytix Biopharma–SEVERAL: investment, 201312 capital increase NOK50m
  Successor Lytix Biopharma–SEVERAL: investment, 201704 private placement NOK60m incl NOK6m from Norwegian Cancer Society
Organisation Money taker Lytix Biopharma AS
Products Product LTX-315 (Lytix Biopharma)
  Product 2 venture capital
     

Lytix Biopharma AS. (12/15/15). "Press Release: Lytix Biopharma Raises Approximately 80 Million NOK".

Lytix Biopharma AS has successfully raised approximately 80 million NOK from new and existing shareholders. The new funding enables the company to continue the development of the company’s cancer immunotherapy project LTX-315 through 2016.

- We are very pleased that new and existing investors share our confidence in the potential for the oncolytic peptide LTX-315 in the rapidly advancing field of immunotherapy. With this new funding in place, we aim to initiate combination trials in order to generate new valuable data, says Lytix Biopharma CEO Unni Hjelmaas.

A total of 224.179 new shares will be issued to existing and new shareholders at a subscription price of NOK 350 per share, increasing the total number of shares in the company to 1.000.381. All of the company’s largest shareholders, including North Murray AS, TAJ Holding AS, Care Holding AS, Lysnes Invest AS, Hopen Invest AS, TAVE Invest AS, Picasso Capital AS and Norinnova Invest AS participated in the share issue.

Arctic Securities has been the advisor and facilitator of this capital raise.


About LTX-315

LTX-315 induces a potent stimulation of an extended range of tumor-specific T-cells attacking cancer, thereby increasing patient specific immune response. LTX-315 “pushes the accelerator” of the immune system through the release of potent immune stimulants. Furthermore, LTX-315 differentiates from many other cancer immunotherapies by inducing the release of an extended range of patient-specific tumor antigens including neo-antigens.

Combinations of complementary immunotherapy treatments are expected to be an integral part of future cancer treatment delivering significant clinical benefit. ICIs “release the brakes” imposed by the tumor on the immune system. LTX-315 has the potential to augment efficacy of ICIs without adding toxicity.


Further information:

Company contact: Unni Hjelmaas (CEO)
Tel (+47) 915 19 651, e-mail: unni.hjelmaas@lytixbiopharma.com

Investment contact: Kjetil Vangsnes (CFO)
Tel (+47) 476 55 336, e-mail: kjetil.vangsnes@lytixbiopharma.com


Lytix Biopharma’s technology is based on nature’s own defense mechanisms. The membranes of cancer cells are destroyed. Our unique technology is a new class of cancer immunotherapy that activates the patient`s own immune system. Lytix Biopharma’s strategy is to develop its drug candidates to end Phase II, and then collaborate with partners for the final stages of product development and commercialization. www.lytixbiopharma.com

   
Record changed: 2017-08-28

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for Lytix Biopharma AS


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top